Pyrazole FFA4 Agonists for CNS Penetration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current FFA4 agonists face challenges in effectively targeting the central nervous system (CNS) due to their carboxylic acid moiety, which hampers their therapeutic potential in neuroinflammation and other CNS-related pathologies.
Innovation Solution
Development of novel pyrazole compounds with specific structural features, such as varying alkyl and aryl substitutions, that enhance cell permeability and CNS penetration, thereby acting as potent FFA4 agonists.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If FFA4 agonists contain a carboxylic acid moiety, then they exhibit potent FFA4 receptor agonistic properties, but their cell permeability and CNS penetration are hampered
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of FFA4 agonists - specifically replacing the carboxylic acid moiety with isoxazole or pyrazole rings containing various substituents (alkyl, aryl, heteroaryl groups). This structural parameter change maintains FFA4 receptor binding affinity while improving cell permeability and enabling CNS penetration, as evidenced by compounds showing potent agonistic activity in vitro and in vivo with enhanced pharmacokinetic properties
Solution Approach 2:
The patent applies local quality by introducing specific substituent patterns at different positions of the isoxazole/pyrazole core structure. Different substituents (electron-withdrawing or electron-donating groups, various alkyl chains, aryl groups) are placed at specific locations to optimize local interactions with the FFA4 receptor while simultaneously improving overall molecular properties for better membrane permeability and CNS delivery
2Reliability
If FFA4 agonists are designed for metabolic disease treatment, then they improve insulin sensitivity and glucose tolerance, but their ability to address neuroinflammatory conditions is limited
Solution Approach 1:
The patent achieves universality by creating FFA4 agonists with dual therapeutic potential - the modified isoxazole/pyrazole compounds maintain efficacy for metabolic diseases (improving insulin sensitivity and glucose tolerance as demonstrated in diabetic models) while simultaneously gaining the ability to cross the blood-brain barrier and treat neuroinflammatory conditions, thus serving multiple therapeutic indications with a single compound class
Data Source
AI summary
Disclosed are compounds of formula (I) or a pharmaceutically acceptable salt thereof:These compounds have FFA4/GPR120 receptor (FFA4) agonistic properties. Also disclosed are pharmaceutical compositions including these compounds, chemical processes for preparing them and their use in the treatment or prophylaxis of diseases associated with FFA4 receptor activity in animals, in particular humans.